Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 7, No 4 (2014) ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... are not interested in price reduction at noncompetitive procedures. In the procurement of alternative drugs ..."
 
Vol 18, No 1 (2025) Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia Abstract  similar documents
A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova
"... of biosimilars on the market for public procurement of medicinal products based mAbs during the period 2022–2023 ..."
 
Vol 17, No 3 (2024) Assessment of the impact of procurement centralization on the drug provision for patients within the High-Cost Nosology Program in the Russian Federation Abstract  similar documents
V. V. Omelyanovskiy, V. A. Ryagina, A. G. Kharitonova, K. I. Matrenin, A. A. Kingshott, O. V. Ashikhmina, M. V. Zhirov
"... centralization on the weighted average price (WAP) per 1 unit of measurement (UM) of a drug, the procurement ..."
 
Vol 18, No 2 (2025) Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration Abstract  similar documents
F. V. Gorkavenko, A. B. Goryachev, O. V. Ashikhmina, D. V. Fedyaev, N. V. Ignateva, E. A. Smolyarchuk, A. V. Kirchenko, D. D. Tkachenko, V. I. Brazhnikova
"... , including assessment of the product range, price dynamics, demand and consumption, as well as index analysis ..."
 
Vol 14, No 4 (2021) Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy Abstract  similar documents
N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev
"... by regions for higher price, and centralized scenario with federal procurements and lower price for the drug ..."
 
Vol 15, No 1 (2022) Study of methods for state regulation of prices and costs of the health care system for medicines in the United Kingdom Abstract  similar documents
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich
"... of prices and costs for the procurement of drugs was carried out based on information contained ..."
 
Vol 12, No 2 (2019) Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available Abstract  similar documents
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev
"... trends in the general picture of drug prices and consumption. In the present study, we analyze ..."
 
Vol 7, No 2 (2014) ANALYSIS OF DRUG PRODUCTS ASSORTMENT ACQUIRABLE BY HEALTHCARE ORGANIZATIONS FOR MEDICAL TREATMENT IN HOSPITAL SETTINGS WAS CONDUCTED Abstract  similar documents
M. G. Malaev
 
Vol 14, No 2 (2021) Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting Abstract  similar documents
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
"... based on the maximum registered prices, recommended doses and treatment regimens. The normative legal ..."
 
Vol 12, No 4 (2019) Clinical and economic analysis of drug costs in a general hospital in 2014-2018 Abstract  similar documents
A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova
"... results prompted a reassessment of the drug procurement policy and readjustment of the financial resources ..."
 
Vol 12, No 4 (2019) Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation Abstract  similar documents
A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev
"... на уровне субъекта РФ по мере истечения сроков патентной защиты лекарственных препаратов (ЛП ..."
 
Vol 18, No 2 (2025) Data analysis of medicines aimed at health technology assessment within the activities of the “Circle of Kindness” Foundation from 2021 to 2024 Abstract  similar documents
V. V. Omelyanovskiy, A. A. Kingshott, T. S. Teptsova, P. A. Mukhortova, A. G. Kharitonova, S. I. Zinadinov, L. O. Krekhtunova, N. A. Aldushchenko, A. А. Kozak, V. A. Ryagina
"... in the procurement lists of the “Circle of Kindness” Foundation is provided by health technology assessment conducted ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..."
 
Vol 10, No 4 (2017) IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET Abstract  similar documents
V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva
"... the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... ) or the ready-made mixtures (biphasic 25 or 50 lispro). The weighted average price of 1 IU insulin (according ..."
 
Vol 11, No 4 (2018) Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer Abstract  similar documents
N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
"... direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment ..."
 
Vol 13, No 2 (2020) Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union Abstract  similar documents
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich
"... Aim. To analyze the methods of the state regulation of prices for the manufacturers ..."
 
Vol 7, No 4 (2014) ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva
"... study goal is to prepare a road map for development of price regulation system and system of drug ..."
 
Vol 17, No 1 (2024) Analysis of the availability of bronchodilators and anti-inflammatory drugs for patients with chronic obstructive pulmonary disease Abstract  PDF (Eng)  similar documents
E. A. Orlova, V. I. Petrov, I. P. Dorfman, O. V. Shatalova, M. A. Orlov
"... in the Russian Federation. Objective: to assess drug prices, affordability, and availability for COPD patients ..."
 
Vol 17, No 4 (2024) The joint use of ABC/VEN analysis and the Beers criteria for optimizing expenditure of funds and rational prescribing of medications to elderly patients Abstract  similar documents
O. A. Makhmudova, G. F. Avkhadieva, O. G. Bagdanova, V. N. Khaziakhmetova
"... ) in A, B, C groups. In 2019, 13.7% of the budget was spent on the procurements of drugs of N category ..."
 
Vol 10, No 2 (2017) COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS Abstract  similar documents
M. B. Kubaeva, Y. Sh. Guchshina
"... -sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy. ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... . The costs in model are calculated on the basis of registered prices on drugs from the List of vital ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA Abstract  similar documents
M. Yu. Frolov, O. V. Shatalova
"... procurement. If introduced this program can save the Federal budget up to 232 785 963 rubles. Conclusion ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... to December 2015. The data of state statistical supervision, registered limit transfer drug prices from ..."
 
Vol 14, No 2 (2021) Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price Abstract  similar documents
D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov
"... as indicated, taking into consideration the new registered price. Material and methods. A clinical-economic ..."
 
Vol 14, No 3 (2021) Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital Abstract  similar documents
L. N. Sheikhmambetova, E. A. Egorova, K. N. Onishchenko, E. I. Konyaeva
"... expenditure was carried out using ABC/VEN analysis. Results. The total expenditure on the procurement ..."
 
Vol 15, No 3 (2022) Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation Abstract  similar documents
N. A. Avxentyev, Yu. V. Makarova
"... state procurement of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in 2021, we ..."
 
Vol 12, No 3 (2019) Clinical and economic analysis as an instrument for harmonizing import substitution in the preferential segment of medicinal support Abstract  similar documents
E. V. Eliseeva , E. S. Maneeva , R. K. Goncharova , A. V. Kropotov
"... analogues) and subjective (irrational approaches to the procurement of medicines due to the lack ..."
 
Vol 18, No 1 (2025) The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market Abstract  similar documents
I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya
"... period, the weighted average price (WAP) per 1 package of a drug for DM treatment increased from 472 ..."
 
Vol 17, No 4 (2024) Pharmacoeconomic study of active psoriatic arthritis treatment Abstract  similar documents
A. V. Rudakova, Т. V. Korotaeva
"... retail prices, inclusive of value-added tax. In case of availability of biosimilars/generics ..."
 
Vol 15, No 3 (2022) Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study Abstract  similar documents
V. V. Strizheletsky, Yu. М. Gomon, Е. А. Spichakova, А. S. Kolbin, А. А. Kalyapin, S. А. Makarov, А. B. Lomiya, F. М. Sultanova
"... . Material and methods. From IQVIA database, the information was selected on retail sales and procurement ..."
 
Vol 14, No 2 (2021) Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care Abstract  similar documents
D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh
"... of palliative care. Materials and methods. The price, affordability and physical availability ..."
 
Vol 15, No 2 (2022) The current state of the veterinary drugs market in the Tyumen Region Abstract  similar documents
V. V. Byshenko, О. I. Knysh, L. N. Zadirachenko, А. О. Egorova, Yu. S. Rodina
"... clinics in the Tyumen Region (33); price lists of veterinary pharmaceutical organizations; questionnaires ..."
 
Vol 13, No 4 (2020) Concept of value-based healthcare Abstract  similar documents
N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov
"... processes including procurement of drugs and medical devices, their pricing, and reimbursement. ..."
 
Vol 10, No 2 (2017) THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS Abstract  similar documents
V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko
"... as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic ..."
 
Vol 16, No 1 (2023) Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 Abstract  similar documents
D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin
"... Information System for Procurement for the period from July to December 2022 inclusive. The budget impact ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
Vol 17, No 2 (2024) Mathematical modeling and analysis of export trends for certain pharmaceutical groups Abstract  similar documents
А. R. Shaikhislamova, N. А. Gasratova
"... on various economic indicators, such as gross domestic product, the volume of government procurement ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... (procurement of essential drugs (EDPP) and of regional benefits (RBP)). Materials and Methods. We collected ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... regimens were calculated from the registered data on the maximum selling prices of VED drugs or from ..."
 
Vol 8, No 3 (2015) COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS Abstract  similar documents
A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova
"... CMC both in quality and price. Results: Based on the assessment of pharmacological quality and price ..."
 
Vol 17, No 4 (2024) Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system Abstract  similar documents
A. V. Rudakova, I. Z. Gaydukova
"... to the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... of orphan drugs and to carry out state regulation of prices, to ensure increase of regional funding ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices ..."
 
Vol 7, No 4 (2014) IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? Abstract  similar documents
V. V. Omelyanovskiy
"... , internal and external price regulation can be distinguished. External referencing system has been used ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia Abstract  similar documents
V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura
"... of antimicrobial treatment calculated with a reference to the price and the percentage of total AMDs administered ..."
 
Vol 14, No 4 (2021) Features of intellectual property protection mechanisms on the example of orphan drugs circulation Abstract  similar documents
D. S. Yurochkin, К. V. Nasonova, Z. М. Golant, I. А. Narkevich, V. P. Trukhin
"... by the regulatory authority, it is necessary to establish reasonable marginal prices, to form a sufficient set ..."
 
Vol 17, No 1 (2024) Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... on the registered prices according to the state register of maximum selling prices. Results. The use ..."
 
1 - 50 of 276 Items 1 2 3 4 5 6 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)